Liquid Biopsy Tracks Herceptin Resistance in HER2+ Gastric Cancer Liquid Biopsy Tracks Herceptin Resistance in HER2+ Gastric Cancer

Circulating tumor DNA profiling can provide novel insights into gene alterations that underlie trastuzumab resistance in HER2+ metastatic gastric cancer.Medscape Medical News
Source: Medscape Pharmacist Headlines - Category: Drugs & Pharmacology Tags: Hematology-Oncology News Source Type: news

Related Links:

Publication date: July 2019Source: The Journal of Molecular Diagnostics, Volume 21, Issue 4Author(s): Sangjoon Choi, Jinah Chu, Binnari Kim, Sang Yun Ha, Seung Tae Kim, Jeeyun Lee, Won Ki Kang, Heewon Han, Insuk Sohn, Kyoung-Mee KimIntratumoral heterogeneity of human epidermal growth factor receptor 2 (HER2) is common in gastric cancer (GC). However, a direct comparison between the results of HER2 immunohistochemistry (IHC) and next-generation sequencing (NGS)–based cancer panel tests has not been explored in GC. We aimed to determine optimal thresholds of HER2 overexpression to be detected by NGS with the data of 16...
Source: The Journal of Molecular Diagnostics - Category: Pathology Source Type: research
Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) announced that the U.S. Food and Drug Administration (FDA) has approved KANJINTITM (trastuzumab-anns) for all approved indications of the reference product, Herceptin® (trastuzumab): for the treatment of HER2-overexpressing adjuvant and metastatic breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Amgen Business and Industry Source Type: news
In this study, we developed a novel anti-HER2 monoclonal antibody (mAb), H2Mab-41 (IgG2b, kappa), and the antitumor activity of H2Mab-41 was investigated using mouse xenograft models. Caco-2 cells (human colon cancer cell line), which expresses HER2, were subcutaneously implanted into the flanks of nude mice. H2Mab-41 and control mouse IgG were injected three times into the peritoneal cavity of mice. H2Mab-41 significantly reduced tumor development of Caco-2 xenograft in comparison with the control mouse IgG on days 5, 8, 11, 15, and 19. Taken together, these results suggest that H2Mab-41 is useful for antibody therapy aga...
Source: Monoclonal Antibodies in Immunodiagnosis and Immunotherapy - Category: Microbiology Tags: Monoclon Antib Immunodiagn Immunother Source Type: research
Authors: Al Diffalha S, Sexton KC, Watson PH, Grizzle WE Abstract Medical research advances enabling the realization of precision medicine have relied heavily on the biospecimens provided by bioresources to identify the targets and biomarkers that are the focus of the new generation of more effective molecular-based therapies for specific subtypes of diseases. Through the biospecimens they have distributed, bioresources have permitted subtypes of cancers to be identified and molecular features of these subtypes to be effectively targeted. A prototype example is the human epidermal growth factor receptor type 2 (HER...
Source: Biopreservation and Biobanking - Category: Biomedical Science Tags: Biopreserv Biobank Source Type: research
Approval Based on Totality of Evidence Demonstrating KANJINTI is Biosimilar to Herceptin Third FDA Approval From Amgen's Biosimilars Portfolio THOUSAND OAKS, Calif., June 13, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) today announced that the U.S. Food and Drug Administration (FDA) has approved KANJINTI™ (trastuzumab-anns) for all approved indications of the reference product, Herceptin® (trastuzumab):  for the treatment of HER2-overexpressing adjuvant and metastatic breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. "...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news
ConclusionIn our analysis, pathological staging and primary site were main prognostic factors. Moreover, a small group of EGJ/HER2+ had very poor survival.
Source: Journal of Gastrointestinal Cancer - Category: Cancer & Oncology Source Type: research
ConclusionsPertuzumab exposure in JACOB was consistent with prior studies in advanced gastric cancer and breast cancer. The 840  mg q3w dose allowed the majority of patients in JACOB to achieve target pertuzumab concentrations and appears to be an appropriate dose selection.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
Purpose of review This manuscript aims at providing an update and overview on the role of Human epidermal growth factor receptor 2 (HER2) testing and HER2-directed therapies in digestive tumors. Recent findings Phase 3 trial data demonstrating a survival benefit of HER2-targeting treatments are limited to gastric cancer. However, HER2 positivity is also found in 5–6% of colorectal, 7% of pancreatic, and 16% of extrahepatic biliary cancers. Although phase 2 trial data support the use of the combination of trastuzumab and lapatinib with chemotherapy in HER2-positive colorectal cancer, the patient's benefit from ta...
Source: Current Opinion in Oncology - Category: Cancer & Oncology Tags: GASTROINTESTINAL TRACT: Edited by Alain Hendlisz Source Type: research
HER2, a member of the epidermal growth factor receptor (EGFR) family, has been associated with human breast, ovarian and gastric cancers. Anti-HER2 monoclonal antibodies (mAbs) have demonstrated clinical efficacy for HER2-overexpressing breast cancer. A chimeric antibody chA21 that specifically inhibits the growth of HER2-overexpressing cancer cells both in vitro and in vivo has previously been developed. To reduce a potential human anti-mouse immune response, the humanized antibody HuA21 was developed and was further subjected to affinity maturation by phage display on the basis of chA21. Here, the crystal structure of Hu...
Source: Acta Crystallographica Section D - Category: Biochemistry Authors: Tags: HER2-overexpressing cancer humanized antibody EGFR family cell signaling crystal structure research papers Source Type: research
10 –20% of patients with gastric cancer (GC) have HER2+ tumors. Addition of trastuzumab (T) to cisplatin/fluoropyrimidine-based chemotherapy (CT) improved survival in metastatic, HER2+ GC. When pertuzumab (P) w...
Source: BMC Cancer - Category: Cancer & Oncology Authors: Tags: Study protocol Source Type: research
More News: Cancer | Cancer & Oncology | Drugs & Pharmacology | Gastric (Stomach) Cancer | Gastroenterology | Genetics | Hematology | HER2 | Herceptin